Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [117 x 33] intentionally omitted <==

**Pharmaron Beijing Co., Ltd.[*] 康龍化成（北京）新藥技術股份有限公司**

(A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 3759)

2021 THIRD QUARTERLY REPORT

This announcement is made by Pharmaron Beijing Co., Ltd.[] (the “ Company ” and together with its subsidiaries, the “ Group* ”) pursuant to Rules 13.09 and 13.10B of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the third quarterly report for 2021 of the Company. The financial data contained in this quarterly report is, except for section (IV) in Part IV which has been prepared in accordance with the International Financial Reporting Standards issued by the International Accounting Standard Board (the “ IFRSs ”) or as otherwise indicated, prepared in accordance with the PRC Accounting Standards for Business Enterprises. The third quarterly report for 2021 of the Company has not been audited.

By order of the Board Pharmaron Beijing Co., Ltd.* 康龍化成（北京）新藥技術股份有限公司 Dr. Lou Boliang Chairman

Beijing, the PRC October 27, 2021

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Chen Guoqin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.

For identification purposes only

**Pharmaron Beijing Co., Ltd.[*] 康龍化成（北京）新藥技術股份有限公司**

6 Tai-He Road, Beijing Economic Technological Development Area, Beijing, China

2021 THIRD QUARTERLY REPORT

October 2021

IMPORTANT NOTICE:

1. The Board of Directors, the Supervisory Committee and the Directors, Supervisors and senior management warrant the truthfulness, accuracy and completeness of the Quarterly Report and that there are no false information, misleading statements or material omissions in the Quarterly Report, and shall assume joint and several legal responsibility.

2. The person in charge of the Company, the Chief Financial Officer and the person in charge of Accounting Department (accounting head) of the Company warrant the truthfulness, accuracy and completeness of the financial information contained in the Quarterly Report.

3. Whether the Third Quarterly Report has been audited

Yes √ No

I. MAJOR FINANCIAL DATA

(I) Major accounting data and financial indicators

Any necessary retrospective adjustment or restatement of the accounting data of the previous years

□ Yes √ No

					Increase/
					(decrease)
					from the
		Increase/			beginning of
		(decrease)			the year to
			for the		the end of
		reporting period			the reporting
		compared		From the	period as
		with the		beginning of	compared
		corresponding		the year to	with the
		period of		the end of the	corresponding
	The reporting	the previous		reporting	period of the
	period		year	period	previous year
Revenue (RMB)	2,016,021,685.34		44.75%	5,301,532,904.44	47.84%
Net profit attributable to owners of the parent (RMB)	475,226,582.02		53.26%	1,040,062,760.57	31.81%
Net profit attributable to owners of the parent
excluding non-recurring gains or losses (RMB)	347,305,923.16		42.63%	930,773,984.67	53.71%
Net cash flows from operating activities (RMB)				1,415,775,594.19	22.15%
Basic earnings per share (RMB/share)	0.5998		52.85%	1.3131	31.63%
Diluted earnings per share (RMB/share)	0.5990		53.24%	1.3104	31.69%
Return on net assets on weighted average basis	4.98%		1.17%	11.18%	1.51%
					Increase/
					(decrease)
					at the end of the
					reporting period
					as compared
					with the end
	As at	the end of	As at the end of		of the
	the reporting period		the previous year		previous year
Total assets (RMB)	17,536,055,892.02		11,908,792,687.05		47.25%
Net assets attributable to owners of the parent (RMB)	9,757,934,948.59		8,870,319,872.38		10.01%

Revenue from principal operations, cost and gross profit margin for the first three quarters of 2021 as well as their period-on-period changes are as follows:

Unit: RMB

							Increase/
							(decrease) in
							revenue as
By products or	From the beginning of the year to			The corresponding period of			compared
services	the end of	the reporting period		the	previous year		with the
			Gross			Gross	corresponding
			profit			profit	period of the
	Revenue	Cost	margin	Revenue	Cost	margin	previous year
Laboratory services	3,301,655,452.35	1,861,116,467.22	43.63%	2,320,501,197.36	1,316,052,504.22	43.29%	42.28%
CMC (small molecule
CDMO) services	1,223,506,278.42	793,112,343.07	35.18%	830,126,012.37	566,854,126.08	31.71%	47.39%
Clinical development
services	664,831,034.16	581,031,417.83	12.60%	413,977,260.18	339,298,415.71	18.04%	60.60%
Biologics and
CGT services	109,400,027.12	126,447,682.27	-15.58%	6,547,524.37	3,936,919.62	39.87%	1,570.86%

The gross profit margin of principal operations in the first three quarters of 2021 was 36.56%, compared with 37.66% in the corresponding period of the previous year. RMB appreciated in the Reporting Period. Should the weighted average USD exchange rate in the Reporting Period remains the same as the same period of last year, the gross profit margin of principal operations for the first three quarters of 2021 will be higher by about 3.38%.

(II) Non-recurring gains or losses items and amounts

√ Applicable □ N/A

Unit: RMB

Item Gains or losses from disposal of non-current assets (including written-off portion of provisions for assets impairment) Government grants included in profit/(loss) of the current period (except for those closely related to the Company’s ordinary business and granted on an ongoing basis under the state’s policies according to certain standard amount or volume) Gains or losses on changes in fair value of arising from held-for-trading financial assets, held-for-trading financial liabilities, and investment income from disposal of held-for-trading financial assets, held-for-trading financial liabilities and available-for-sale financial assets, except effective hedging activities related to the Company’s normal business operations Other non-operating income and expenses other than the above items Less: Effect of income tax Impact on non-controlling interests (after tax) Total	The reporting period -268,503.87 8,280,693.70 122,503,784.40 267,067.77 2,385,675.50 476,707.64 127,920,658.86	From the beginning of the year to the end of the reporting period Note -1,140,189.77 31,794,196.34 It was mainly due to government subsidies related to daily activities that were received by the Company during the reporting period. 98,241,178.67 It mainly includes: (1) gains on change in fair value of other non-current financial assets of the Company from the beginning of the year to the end of the reporting period amounted to approximately RMB59,008,100; (2) from the beginning of the year to the end of the reporting period, income related to wealth management products amounted to approximately RMB34,974,500; (3) from the beginning of the year to the end of the reporting period, the losses on change in fair value from the convertible bonds-embedded derivative component was approximately RMB27,111,300 which was affected by the fluctuation in the share price of the Company’s H Shares; (4) from the beginning of the year to the end of the reporting period, gains resulting from transfer of an investment in associate, Shanghai Kejun Pharmaceutical Technology Co., Ltd. (上海柯君醫藥科技有限公司), to equity investments at fair value through profit or loss amounted to approximately RMB25,451,700. -4,749,227.22 11,548,612.44 3,308,569.68 109,288,775.90

Other specific circumstances of gains or losses items that meet the definition of non-recurring gains or losses:

□ Applicable √ N/A

The Company did not have other specific circumstances of gains or losses items that meet the definition of non-recurring gains or losses.

Description of non-recurring gains or losses items as illustrated in the Explanatory Announcement No. 1 for Information Disclosure by Public Issuers of Securities – Non-recurring Gains or Losses Items defined as recurring gains or losses items:

□ Applicable √ N/A

The Company did not list any non-recurring gains or losses items as illustrated in the Explanatory Announcement No. 1 for Information Disclosure by Public Issuers of Securities – Non-recurring Gains or Losses Items as recurring gain or loss items.

(III) Change in major accounting data and financial indicators and the reasons thereof

√ Applicable □ N/A

	As at the end
	of the reporting	As at the
	period/from the	end of the
	beginning of the	previous year/the
	year to the end	corresponding
	of the reporting	period of the	Percentage
Item	period	previous year	of changes	Reasons for changes
	(RMB)	(RMB)
Revenue	5,301,532,904.44	3,585,968,004.69	47.84%	Revenue increased by 47.84% on a period-on-period basis from
				the beginning of the year to the end of the reporting period,
				mainly due to the Company’s overall development in good
				shape with ever-growing income.
Net profit attributable to	1,040,062,760.57	789,043,085.87	31.81%	Net profit attributable to owners of the parent increased by
owners of the parent				31.81% on a period-on-period basis from the beginning of
				the year to the end of the reporting period, mainly due to the
				further increase from economies of scale under the growth in
				revenue.
Net profit attributable	930,773,984.67	605,543,225.57	53.71%	Net profit attributable to owners of the parent excluding non-
to owners of the parent				recurring gains or losses increased by 53.71% on a period-
excluding non-recurring				on-period basis from the beginning of the year to the end of
gains or losses				the reporting period, mainly due to the further increase from
				economies of scale under the growth in revenue.
Basic earnings per share	1.3131	0.9976	31.63%	It was mainly due to the increase in net profit attributable to
				owners of the parent from the beginning of the year to the
				end of the reporting period compared with the corresponding
				period of the previous year.

	As at the end
	of the reporting	As at the
	period/from the	end of the
	beginning of the	previous year/the
	year to the end	corresponding
	of the reporting	period of the	Percentage
Item	period	previous year	of changes	Reasons for changes
	(RMB)	(RMB)
Diluted earnings	1.3104	0.9951	31.69%	It was mainly due to the increase in net profit attributable to
per share				owners of the parent from the beginning of the year to the
				end of the reporting period compared with the corresponding
				period of the previous year.
Total assets	17,536,055,892.02	11,908,792,687.05	47.25%	Total assets increased by RMB5,627,263,200 as compared
				with the balance at the end of last year, representing an
				increase of 47.25%, including: cash and bank balances
				increased by RMB1,347,519,400, fixed assets increased
				by RMB878,113,500, held-for-trading financial assets
				increased by RMB751,942,300, goodwill increased by
				RMB647,638,200 and other current assets increased by
				RMB521,458,600.
Cash and bank balances	4,289,872,163.19	2,942,352,739.79	45.80%	Cash and bank balances increased by RMB1,347,519,400
				as compared with the balance at the end of last year,
				representing an increase of 45.80%, which was mainly due
				to the receipt of proceeds of convertible bonds during the
				reporting period.
Held-for-trading	1,661,952,546.61	910,010,204.36	82.63%	Held-for-trading financial assets increased by RMB751,942,300
financial assets				as compared with the balance at the end of last year,
				representing an increase of 82.63%, which was mainly due
				to the increase in holding medium-risk and low-risk wealth
				management products invested with the Company’s own
				funds.
Prepayments	29,745,892.90	9,991,377.35	197.72%	Prepayments increased by RMB19,754,500 as compared with
				the balance at the end of last year, representing an increase
				of 197.72%, which was mainly due to the increase in
				prepayments for purchases of raw material.
Other receivables	91,514,694.43	43,125,212.21	112.21%	Other receivables increased by RMB48,389,500 as compared
				with the balance at the end of last year, representing an
				increase of 112.21%, which was mainly due to the increase
				in tax refund subsidy receivable.

	As at the end
	of the reporting	As at the
	period/from the	end of the
	beginning of the	previous year/the
	year to the end	corresponding
	of the reporting	period of the	Percentage
Item	period	previous year	of changes	Reasons for changes
	(RMB)	(RMB)
Inventories	567,550,470.51	281,617,169.89	101.53%	Inventories increased by RMB285,933,300 as compared with
				the balance at the end of last year, representing an increase
				of 101.53%. Major changes are as follows:
				(1) the Company acquired Biomedical Research (GZ), Ltd.
				(肇慶創藥生物科技有限公司) during the reporting period
				and the consumable biological assets increased as a result
				of business combination not under common control;
				(2) the consumable biological assets purchased based on our
				business demand during the reporting period;
				(3) the increase in raw materials reserved based on our
				business demand and products under production during
				the reporting period.
Contract assets	187,237,361.85	133,764,197.46	39.98%	Contract assets increased by RMB53,473,200 as compared with
				the balance at the end of last year, representing an increase
				of 39.98%, which was mainly due to the growing business
				scale.
Other current assets	664,362,148.85	142,903,541.28	364.90%	Other current assets increased by RMB521,458,600 as compared
				with the balance at the end of last year, representing an
				increase of 364.90%, which was mainly due to the increase in
				fixed-income wealth management products included in other
				current assets.
Long-term equity	375,737,637.20	280,474,146.47	33.97%	Long-term equity investments increased by RMB95,263,500
investments				as compared with the balance at the end of last year,
				representing an increase of 33.97%, which was mainly due
				to the new equity investments of RMB78,000,000 in Ningbo
				Kangjun Zhongyuan Equity Investment Partnership (Limited
				Partnership) (寧波康君仲元股權投資合夥企業(有限合夥))
				during the reporting period.

	As at the end
	of the reporting	As at the
	period/from the	end of the
	beginning of the	previous year/the
	year to the end	corresponding
	of the reporting	period of the	Percentage
Item	period	previous year	of changes	Reasons for changes
	(RMB)	(RMB)
Other non-current	282,253,591.56	121,229,605.93	132.83%	Other non-current financial assets increased by RMB161,024,000
financial assets				as compared with the balance at the end of last year,
				representing an increase of 132.83%. Major changes are as
				follows: (1) transfer of an investment in associate, Shanghai
				Kejun Pharmaceutical Technology Co., Ltd., to equity
				investments at fair value through profit or loss amounted to
				approximately RMB31,816,700 during the reporting period;
				(2) new investments of RMB36,190,900 in Beijing Legend
				Huikang Equity Investment Partnership (Limited Partnership)
				(北京君聯惠康股權投資合夥企業(有限合夥)) during the
				reporting period; (3) new investments of RMB29,000,000
				in Wuxi AstraZeneca CICC Venture Capital Partnership
				(Limited Partnership) (無錫阿斯利康中金創業投資合夥企業
				(有限合夥)) during the reporting period; (4) gains on change
				in fair value of other non-current financial assets of the
				Company from the beginning of the year to the end of the
				reporting period amounted to approximately RMB59,008,100.
Investment properties	–	43,888,859.93	-100.00%	It was due to the conversion of use of investment properties
				to its own use during the reporting period, resulting in the
				transfer of relevant land and buildings to intangible assets
				and fixed assets, respectively.
Fixed assets	3,600,800,496.89	2,722,686,958.65	32.25%	Fixed assets increased by RMB878,113,500 as compared with
				the balance at the end of last year, representing an increase of
				32.25%, which was mainly due to the purchase and transfer
				from construction in progress during the period.
Construction in progress	1,161,983,279.02	820,576,183.15	41.61%	Construction in progress increased by RMB341,407,100
				as compared with the balance at the end of last year,
				representing an increase of 41.61%, which was mainly due
				to the scheduled construction of Ningbo Hangzhou Bay R&D
				service center, Shaoxing Phase I facility, Ningbo Hangzhou
				Bay service center II Phase I.
Productive	39,136,292.88	–	N/A	Biomedical Research (GZ), Ltd. was acquired during the
biological assets				reporting period and the productive biological assets
				increased as a result of business combination not under
				common control.
Goodwill	1,813,810,478.98	1,166,172,234.71	55.54%	Goodwill increased by RMB647,638,200 as compared with the
				balance at the end of last year, representing an increase of
				55.54%, which was mainly due to the business combination
				not under common control of Pharmaron Biologics (UK) Ltd
				and Biomedical Research (GZ), Ltd. during the reporting
				period.

	As at the end
	of the reporting	As at the
	period/from the	end of the
	beginning of the	previous year/the
	year to the end	corresponding
	of the reporting	period of the	Percentage
Item	period	previous year	of changes	Reasons for changes
	(RMB)	(RMB)
Deferred tax assets	15,557,071.21	8,436,003.69	84.41%	Deferred tax assets increased by RMB7,121,100 as compared
				with the balance at the end of last year, representing an
				increase of 84.41%, which was mainly due to the increase in
				the deferred tax assets related to the share-based payments
				during the reporting period.
Other non-current assets	455,788,904.69	149,162,761.67	205.56%	Other non-current assets increased by RMB306,626,100
				as compared with the balance at the end of last year,
				representing an increase of 205.56%, which was mainly due
				to the increase in prepayments for equipment and equity
				interests.
Trade payables	283,661,986.37	191,497,239.86	48.13%	Trade payables increased by RMB92,164,700 as compared with
				the balance at the end of last year, representing an increase
				of 48.13%, which was mainly due to the increase in the
				purchase of raw materials.
Contract liabilities	662,177,001.95	473,288,883.77	39.91%	Contract liabilities increased by RMB188,888,100 as compared
				with the balance at the end of last year, representing an
				increase of 39.91%, which was mainly due to the expansion
				of business scale.
Tax payables	123,140,500.50	51,834,011.70	137.57%	Tax payables increased by RMB71,306,500 as compared with
				the balance at the end of last year, representing an increase
				of 137.57%, which was mainly due to the significant growth
				of the total profit during the reporting period, resulting in a
				greater increase in the income tax payable compared with the
				balance at the end of last year.
Long-term borrowings	933,201,421.61	394,810,891.08	136.37%	Long-term borrowings increased by RMB538,390,500
				as compared with the balance at the end of last year,
				representing an increase of 136.37%, which was mainly due
				to the increased bank borrowings for project construction.
Bond payables	3,470,088,077.90	–	N/A	Bond payables increased by RMB3,470,088,100 as compared
				with the balance at the end of last year, which was mainly
				due to the issuance of zero coupon convertible bonds due
				2026 on The Stock Exchange of Hong Kong Limited during
				the reporting period.
Other equity instruments	198,554,160.44	–	N/A	Other equity instruments increased by RMB198,554,200 as
				compared with the balance at the end of last year, which was
				mainly due to the Company successfully issued principal
				amount of US$300,000,000 zero coupon convertible bonds
				due 2026 and principal amount of RMB1,916,000,000 zero
				coupon US$-settled convertible bonds due 2026 on The Stock
				Exchange of Hong Kong Limited, of which the conversion
				option corresponding to the RMB principal bonds was
				included in other equity instruments.

	As at the end
	of the reporting	As at the
	period/from the	end of the
	beginning of the	previous year/the
	year to the end	corresponding
	of the reporting	period of the	Percentage
Item	period	previous year	of changes	Reasons for changes
	(RMB)	(RMB)
Treasury shares	145,240,760.15	45,474,869.16	219.39%	Treasury shares increased by RMB99,765,900 as compared with
				the balance at the end of last year, representing an increase
				of 219.39%. During the reporting period, in accordance with
				the First H Share Award and Trust Scheme, Computershare
				Hong Kong Trustees Limited purchased the H Shares from
				the open market based on the instructions of the Company.
Other comprehensive	-92,119,896.57	-38,224,635.89	-141.00%	Other comprehensive income decreased by RMB53,895,300
income				as compared with the balance at the end of last year,
				representing a decrease of 141.00%, which was mainly due to
				changes in the exchange differences arising from translation
				of foreign currency financial statements during the reporting
				period.
Retained earnings	2,730,900,527.50	1,929,024,059.21	41.57%	From the beginning of the year to the end of the reporting
				period, net profit attributable to owners of the parent
				amounted to approximately RMB1,040,062,800, and
				cash dividends of RMB238,136,300 were distributed to
				shareholders, which together led to an increase in retained
				earnings compared with the balance at the end of last year.
Non-controlling interests	145,993,766.41	63,420,201.85	130.20%	Non-controlling interests increased by RMB82,573,600
				as compared with the balance at the end of last year,
				representing an increase of 130.20%, which was mainly due
				to the business combination not under common control of
				Biomedical Research (GZ), Ltd. during the reporting period.
Cost	3,362,990,019.03	2,232,455,980.47	50.64%	In line with the increased revenue, the cost from the beginning
				of the year to the end of the reporting period increased by
				50.64% on a period-on-period basis.
Taxes and surcharges	32,743,189.82	24,407,708.64	34.15%	It was mainly due to the increase in property tax from the
				beginning of the year to the end of the reporting period
				compared to the same period last year.
Selling expenses	104,381,393.02	65,228,176.03	60.03%	In line with the increased revenue, the selling expenses from
				the beginning of the year to the end of the reporting period
				increased by 60.03% on a period-on-period basis.
Administrative expenses	598,348,091.85	446,635,747.31	33.97%	Administrative expenses increased by RMB151,712,300,
				representing an increase of 33.97% on a period-on-period
				basis from the beginning of the year to the end of the
				reporting period, mainly due to an increase in the number of
				the Company’s executives and labor costs as a result of the
				expansion of the Company’s business scale.

	As at the end
	of the reporting	As at the
	period/from the	end of the
	beginning of the	previous year/the
	year to the end	corresponding
	of the reporting	period of the	Percentage
Item	period	previous year	of changes	Reasons for changes
	(RMB)	(RMB)
Research and	109,851,832.35	69,047,547.25	59.10%	Research and development costs increased by RMB40,804,300,
development costs				representing an increase of 59.10% on a period-on-period
				basis from the beginning of the year to the end of the
				reporting period, mainly due to the Company’s enhanced
				efforts to improve research and development capabilities and
				technical expertise, and increased research and development
				spending.
Finance expenses	11,706,694.10	24,921,867.42	-53.03%	From the beginning of the year to the end of the reporting
				period, there was a significant decrease in losses from foreign
				exchange and an increase in interest expenses, which together
				led to a decrease in finance expenses.
Investment income	135,714,820.76	11,549,584.86	1,075.06%	Investment income increased by RMB124,165,200, representing
				an increase of 1,075.06% on a period-on-period basis from
				the beginning of the year to the end of the reporting period,
				mainly due to:
				(1) the transfer of gains on change in fair value amounting
				to approximately RMB71,164,600 to investment income
				as a result of the settlement of foreign currency forward
				contracts used for hedging against foreign exchange
				risks from the beginning of the year to the end of the
				reporting period, as compared to the gains arising from
				investment in derivative financial instruments amounting
				to RMB4,256,300 in the same period last year;
				(2) the amount of investment income recognized from wealth
				management products was approximately RMB47,253,000
				from the beginning of the year to the end of the reporting
				period, as compared to the amount of investment income
				recognized from wealth management products amounting
				to approximately RMB6,374,800 in the same period last
				year.

	As at the end
	of the reporting	As at the
	period/from the	end of the
	beginning of the	previous year/the
	year to the end	corresponding
	of the reporting	period of the	Percentage
Item	period	previous year	of changes	Reasons for changes
	(RMB)	(RMB)
Gains on change	-33,921,543.15	137,950,949.67	-124.59%	Gains on change in fair value decreased by RMB171,872,500,
in fair value				representing a decrease of 124.59% on a period-on-period
				basis from the beginning of the year to the end of the
				reporting period, mainly due to:
				(1) the losses on change in fair value recognized for
				the foreign currency forward contracts and foreign
				currency option contracts amounting to approximately
				RMB65,246,300 from the beginning of the year to the
				end of the reporting period (mainly the portion of changes
				in fair value of contracts due for settlement transferred to
				investment income), as compared to the gains on change
				in fair value of derivative financial instruments amounting
				to RMB46,430,600 in the same period last year;
				(2) from the beginning of the year to the end of the reporting
				period, the losses on change in fair value from the
				convertible bonds-embedded derivative component was
				RMB27,111,300 which was affected by the fluctuation in
				the share price of the Company’s H Shares;
				(3) gains on change in fair value of other non-current
				financial assets of the Company amounting to
				approximately RMB59,008,100 from the beginning of
				the year to the end of the reporting period, as compared
				to the gains on change in fair value amounting to
				RMB81,838,900 in the same period last year.
Credit impairment losses	-5,161,897.48	-2,688,495.36	92.00%	It was due to the increase in impairment losses on trade
				receivables from the beginning of the year to the end of the
				reporting period.
Assets impairment losses	-1,480,290.23	-3,441,539.26	-56.99%	It was due to the period-on-period decrease in impairment losses
				on inventories and impairment losses on contract assets from
				the beginning of the year to the end of the reporting period.
Gains on disposal of assets	-1,140,189.77	-705,480.17	-61.62%	It was due to an increase in losses arising from the disposal of
				non-current assets from the beginning of the year to the end
				of the reporting period.
Non-operating income	2,051,440.89	627,766.26	226.78%	It was mainly due to the increase in government subsidies
				related to non-daily activities received by the Company
				during the reporting period as compared with the same period
				last year.
Income tax expenses	198,639,330.33	126,974,075.57	56.44%	From the beginning of the year to the end of the reporting
				period, the income tax expenses increased due to a period-
				on-period increase in profit before tax by 34.64%.

II. SHAREHOLDER INFORMATION

(I) Total number of ordinary shareholders and preferred shareholders whose voting rights have been reinstated, and shareholdings of top 10 shareholders

Unit: share

Total number of ordinary shareholders as 24,003 T o t a l n u m b e r o f p r e f e r r e d 0 at the end of the reporting period shareholders whose voting rights have been reinstated as at the end of the reporting period (if any)

Shareholdings of top 10 shareholders

				Number
				of Shares
				subject	Pledged, marked or
			Number	to trading	frozen shares
Name of shareholder	Nature of shareholder	Percentage	of shares	restrictions	Status	Number
Shenzhen Xinzhong Kangcheng Investment	Domestic non-state-owned	19.78%	157,142,855	157,142,855
Partnership (Limited Partnership) (深圳市	legal person
信中康成投資合夥企業(有限合夥))
HKSCC NOMINEES LIMITED	Overseas legal person	16.87%	133,996,893	0
PHARMARON HOLDINGS LIMITED	Overseas legal person	12.29%	97,600,003	97,600,003
Tianjin Junlian Wenda Equity Investment	Domestic non-state-owned	6.39%	50,742,928	0
Partnership (Limited Partnership) (天津	legal person
君聯聞達股權投資合夥企業(有限合夥))
Hong Kong Securities Clearing Company Limited	Overseas legal person	4.91%	39,021,372	0
Shenzhen Xinzhong Longcheng Investment
Partnership (Limited Partnership) (深圳市	Domestic non-state-owned	3.59%	28,494,266	28,494,266
信中龍成投資合夥企業(有限合夥))	legal person
Mr. LOU Xiaoqiang (樓小強)	Domestic natural person	3.46%	27,500,000	27,500,000	Pledge	400,000
Ningbo Longtaikang Investment Management	Domestic non-state-owned	3.46%	27,500,000	27,500,000	Pledge	8,930,000
Co., Ltd. (寧波龍泰康投資管理有限公司)	legal person
Industrial and Commercial Bank of China
Limited-Zhong Ou AMC Medical and Health	Domestic non-state-owned	3.02%	23,998,877	0
Hybrid Securities Investment Fund	legal person
(中國工商銀行股份有限公司－
中歐醫療健康混合型證券投資基金)
Beijing Duotai Investment Management	Domestic non-state-owned	2.61%	20,723,103	20,723,103	Pledge	5,550,000
Co., Ltd. (北京多泰投資管理有限公司)	legal person

Shareholdings of top 10 holders of shares not subject to trading restrictions

Unit: share

	Number
	of shares
	not subject
	to trading	Class of	shares
Name of shareholder	restrictions	Class	Number
HKSCC NOMINEES LIMITED	133,996,893	Overseas listed	133,996,893
		foreign shares
Tianjin Junlian Wenda Equity Investment	50,742,928	RMB-denominated	50,742,928
Partnership (Limited Partnership) (天津		ordinary shares
君聯聞達股權投資合夥企業(有限合夥))
Hong Kong Securities Clearing	39,021,372	RMB-denominated	39,021,372
Company Limited		ordinary shares
Industrial and Commercial Bank of China	23,998,877	RMB-denominated	23,998,877
Limited-Zhong Ou AMC Medical and		ordinary shares
Health Hybrid Securities Investment Fund
(中國工商銀行股份有限公司－
中歐醫療健康混合型證券投資基金)
Mr. YU Yuejiang (郁岳江)	10,584,842	RMB-denominated	10,584,842
		ordinary shares
Bank of China Limited – GF Healthcare	4,325,430	RMB-denominated	4,325,430
Equity Securities Investment Fund		ordinary shares
(中國銀行股份有限公司－
廣發醫療保健股票型證券投資基金)
Beijing Junlian Maolin Equity Investment	3,875,043	RMB-denominated	3,875,043
Partnership (Limited Partnership) (北京		ordinary shares
君聯茂林股權投資合夥企業(有限合夥))
China Construction Bank Corporation –	3,794,756	RMB-denominated	3,794,756
China Universal Innovation Pharmaceuticals		ordinary shares
Theme Mixed Securities Investment Fund
(中國建設銀行股份有限公司－
匯添富創新醫藥主題混合型證券投資基金)
Industrial and Commercial Bank of China	3,600,575	RMB-denominated	3,600,575
Limited – Lombarda China Medical		ordinary shares
Innovation Equity Securities Investment
Fund (中國工商銀行股份有限公司－
中歐醫療創新股票型證券投資基金)
China Construction Bank Corporation –	3,000,011	RMB-denominated	3,000,011
GF Growth Selected Mixed Securities		ordinary shares
Investment Fund (中國建設銀行股份有限
公司－廣發成長精選混合型證券投資基金)

Description of connected relationships or concerted actions of the above shareholders

Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Partnership) (深圳市信中康成投資合夥企業(有限合夥)) and Shenzhen Xinzhong Longcheng Investment Partnership (Limited Partnership) (深圳市信中龍成投資合夥企業(有限合夥)) are the shareholding entities controlled by CITIC M&A Fund Management Co., Ltd. (中信併購基金管理有限公司).
Tianjin Junlian Wenda Equity Investment Partnership (Limited Partnership) (天津君聯聞達股權投資合夥企業(有限合夥)) and Beijing Junlian Maolin Equity Investment Partnership (Limited Partnership) (北京君聯茂林股權投資合夥企業(有限合夥)) are controlled by Junlian Capital Management Co., Ltd. (君聯資本管理股份有限公司).
Mr. LOU Xiaoqiang (樓小強), a shareholder of the Company, owns 100% equity interests of Ningbo Longtaikang Investment Management Co., Ltd. (寧波龍泰康投資管理有限公司); Ms. ZHENG Bei (鄭北), Mr. LOU Xiaoqiang (樓小強)’s spouse, owns 100% equity interests of Beijing Duotai Investment Management Co., Ltd. ( 北京多泰投資管理有限公司 ), and Dr. LOU Boliang (樓柏良), Mr. LOU Xiaoqiang (樓小強)’s brother, is the director of Pharmaron Holdings Limited.

The top 10 shareholders of the Company have no connected relationship other than those set forth above.

Description of securities margin trading business by top 10 shareholders (if any)

N/A

(II) Number of preferred shareholders and the shareholdings of top 10 preferred shareholders

□ Applicable √ N/A

(III) Change in shares subject to trading restrictions

Applicable √ N/A

III. OTHER SIGNIFICANT EVENTS

√ Applicable □ N/A

(I) Acquisition of 100% equity interest in Zhongke Lingrui (Zhanjiang) Biotechnology Co., Ltd.

In August 2021, the Company reached an acquisition agreement with the shareholders of Zhongke Lingrui (Zhanjiang) Biotechnology Co., Ltd. (“Zhongke Lingrui”) to acquire 100% equity interest in Zhongke Lingrui held by Beijing Prima Biotech Inc. (北京中科靈瑞生物技術股份有限公司) and Ms. Tang Muxiu (湯木秀). Zhongke Lingrui was mainly engaged in experimental animal breeding. The transaction was completed in October 2021, and Zhongke Lingrui is now renamed Kangruitai (Zhanjiang) Biotechnology Co., Ltd. (康瑞泰(湛江)生物技術有限公司).

(II) Summary of announcements on progress of other significant events

Disclosure Overview date of interim Search index on the website disclosing of events announcement the interim announcements 2021 A Share July 12, 2021 2021 Restricted A Share Incentive Scheme Incentive Scheme of Pharmaron Beijing Co., Ltd., disclosure website: (https://www1.hkexnews.hk) (I) Poll Results of the First Extraordinary General Meeting of 2021, the Second A Shares Class Meeting of 2021 and the Second H Shares Class Meeting of 2021 Held on July 12, 2021; and (II) Amendments to the Articles of Association, disclosure website: (https://www1.hkexnews.hk) July 27, 2021 Announcement on Adjustment to the Grant Price of the 2021 Restricted A Share Incentive Scheme and Grant Restricted Shares to Participants and List of Participants (on the Grant Date), disclosure website: (https://www1.hkexnews.hk) Investment in Ningbo July 15, 2021 Announcement on Progress of Investment Kangjun Zhongyuan in Private Equity Investment Fund and Equity Investment Related Transactions, disclosure website: Partnership (Limited (https://www1.hkexnews.hk) Partnership) August 12, 2021 Connected Transaction in Relation to Investment in the Kangjun Zhongyuan Fund, disclosure website: (https://www1.hkexnews.hk) August 12, 2021 Announcement on Progress of Investment in Private Equity Investment Fund and Related Transactions of Pharmaron Beijing Co., Ltd., disclosure website: (https://www1.hkexnews.hk) August 17, 2021 Supplemental Announcement Connected T r a n s a c t i o n , d i s c l o s u r e w e b s i t e : (https://www1.hkexnews.hk) September 10, 2021 Announcement on Completion of Filing of Investment in Private Equity Investment Fund by Pharmaron Beijing Co., Ltd., disclosure website: (https://www1.hkexnews.hk)

Overview of events

Disclosure date of interim Search index on the website disclosing announcement the interim announcements

Investment in Beijing Legend Huikang Equity Investment Partnership
July 27, 2021
(Limited Partnership) Progress of acquisition of August 29, 2021
100% equity interests in Absorption Systems LLC and its whollyowned subsidiaries
Connected Transaction in Relation to Investment in the Legend Huikang Fund, disclosure website: (https://www1.hkexnews.hk)
Update Announcement in Relation to Discloseable Transaction, disclosure website: (https://www1.hkexnews.hk)

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Financial Statements

1. Consolidated Balance Sheet

Prepared by: Pharmaron Beijing Co., Ltd.

Item Current assets: Cash and bank balances Deposit reservation for balance Lending to banks and other financial institutions Held-for-trading financial assets Derivative financial assets Note receivables Trade receivables Trade receivables financing Prepayments Premium receivables Reinsurance account receivables Reinsurance deposit receivables Other receivables Including: Interest receivables Dividend receivables Financial assets held under repurchase agreements Inventories Contract assets Assets held for sale Non-current assets due within one year Other current assets Total current assets	September 30, 2021 4,289,872,163.19 1,661,952,546.61 1,162,676,195.49 29,745,892.90 91,514,694.43 567,550,470.51 187,237,361.85 664,362,148.85 8,654,911,473.83	Unit: RMB December 31, 2020 2,942,352,739.79 910,010,204.36 1,076,613,848.97 9,991,377.35 43,125,212.21 281,617,169.89 133,764,197.46 142,903,541.28 5,540,378,291.31

September 30, December 31, Item 2021 2020

Non-current assets: Disbursement of loans and advances Debt investments Other debt investments Long-term receivables Long-term equity investments Other investments in equity instruments Other non-current financial assets Investment properties Fixed assets Construction in progress Productive biological assets Oil & gas assets Right-of-use assets Intangible assets Development expenses Goodwill Long-term deferred expenses Deferred tax assets Other non-current assets Total non-current assets Total assets	375,737,637.20 282,253,591.56 3,600,800,496.89 1,161,983,279.02 39,136,292.88 298,248,437.20 649,751,315.66 1,813,810,478.98 188,076,912.90 15,557,071.21 455,788,904.69 8,881,144,418.19 17,536,055,892.02	280,474,146.47 121,229,605.93 43,888,859.93 2,722,686,958.65 820,576,183.15 255,439,849.20 566,076,376.97 1,166,172,234.71 234,271,415.37 8,436,003.69 149,162,761.67
		6,368,414,395.74

		11,908,792,687.05

Item Current liabilities: Short-term borrowings Borrowings from the Central Bank Borrowings from banks and other financial institutions Held-for-trading financial liabilities Derivative financial liabilities Note payables Trade payables Advances from customers Contract liabilities Financial assets sold for repurchase Customer and inter-bank deposits Deposit for securities trading brokerage Deposit for securities underwriting brokerage Employee benefits payables Tax payables Other payables Including: Interests payables Dividend payables Fees and commissions payables Reinsurance account payables Liabilities held for sale Non-current liabilities due within one year Other current liabilities Total current liabilities	September 30, 2021 407,453,820.06 283,661,986.37 662,177,001.95 444,161,084.48 123,140,500.50 524,174,682.54 1,382,023.07 107,121,540.10 2,551,890,616.00	December 31, 2020 377,265,354.81 191,497,239.86 473,288,883.77 387,442,503.10 51,834,011.70 407,655,814.57 611,608.05 92,805,094.82 1,981,788,902.63

Item
Non-current liabilities:
Insurance contract reserves
Long-term borrowings
Bond payables
Including: Preferred shares
Perpetual bonds
Lease liabilities
Long-term payables
Long-term employee benefits payables
Provisions
Deferred income
Deferred tax liabilities
Other non-current liabilities
Total non-current liabilities
Total liabilities
Equity:
Share capital
Other equity instruments
Including: Preferred shares
Perpetual bonds
Capital reserve
Less: Treasury shares
Other comprehensive income
Specific reserve
Surplus reserve
General risk provision
Retained earnings
Total equity attributable to the owners of the parent
Non-controlling interests
Total equity
Total liabilities and equity
Legal representative:
Chief Financial Officer:
LOU Boliang
LI Shing Chung Gilbert

September 30,
2021
December 31,
2020
933,201,421.61
394,810,891.08
3,470,088,077.90
227,179,515.15
186,607,862.14
152,566,920.24
158,128,263.67
115,676,589.05
106,906,443.30
181,524,037.07
146,810,250.00
5,080,236,561.02
993,263,710.19
7,632,127,177.02
2,975,052,612.82
794,177,098.00
794,387,462.00
198,554,160.44
6,069,198,564.12
6,028,142,600.97
145,240,760.15
45,474,869.16
-92,119,896.57
-38,224,635.89
202,465,255.25
202,465,255.25
2,730,900,527.50
1,929,024,059.21
9,757,934,948.59
8,870,319,872.38
145,993,766.41
63,420,201.85
9,903,928,715.00
8,933,740,074.23
17,536,055,892.02
11,908,792,687.05
Person in charge of
Accounting Department:
LI Shing Chung Gilbert

2. Consolidated Income Statement from the Beginning of the Year to the End of the Reporting Period

Unit: RMB

Amount of the Amount of the Item current period previous period 1. Total revenue 5,301,532,904.44 3,585,968,004.69 Including: Revenue 5,301,532,904.44 3,585,968,004.69 Interest income Insurance premium earned Fee and commission income 2. Total cost 4,220,021,220.17 2,862,697,027.12 Including: Cost 3,362,990,019.03 2,232,455,980.47 Interest expenses Fee and commission expenses Surrender value Net claim paid Net change in insurance contract reserves Insurance policy dividend paid Reinsurance expenses Taxes and surcharges 32,743,189.82 24,407,708.64 Selling expenses 104,381,393.02 65,228,176.03 Administrative expenses 598,348,091.85 446,635,747.31 Research and development costs 109,851,832.35 69,047,547.25 Finance expenses 11,706,694.10 24,921,867.42 Including: Interest expenses 48,844,259.84 17,642,643.61 Interest income 44,777,111.05 58,681,756.15 Add: Other income 30,497,021.52 31,838,399.98 Investment income (“-” indicating loss) 135,714,820.76 11,549,584.86 Including: Income from investments in associates and joint ventures -8,154,449.19 -22,204,377.15 Gains on derecognition of financial assets measured at amortized cost Foreign exchange gains (“-” indicating loss) Net gain on exposure hedging (“-” indicating loss) Gains on change in fair value (“-” indicating loss) -33,921,543.15 137,950,949.67 Credit impairment losses (“-” indicating loss) -5,161,897.48 -2,688,495.36 Assets impairment losses (“-” indicating loss) -1,480,290.23 -3,441,539.26 Gains on disposal of assets (“-” indicating loss) -1,140,189.77 -705,480.17

Item

1. Total revenue Including: Revenue Interest income Insurance premium earned Fee and commission income

				Amount of the	Amount of the
Item				current period	previous period
3.	Operating profit (“-” indicating loss)			1,206,019,605.92	897,774,397.29
	Add: Non-operating income			2,051,440.89	627,766.26
	Less:	Non-operating expenses		5,503,493.29	5,201,032.00
4.	Profit before tax (“-” indicating total loss)			1,202,567,553.52	893,201,131.55
	Less:	Income tax expenses		198,639,330.33	126,974,075.57
5.	Net profit (“-” indicating net loss)			1,003,928,223.19	766,227,055.98
	(i)	By continuity of operations
		1.	Net profit from continuing operations
			(“-” indicating net loss)	1,003,928,223.19	766,227,055.98
		2.	Net profit from discontinued operations
			(“-” indicating net loss)
	(ii)	By ownership
		1.	Net profit attributable to owners of
			the parent	1,040,062,760.57	789,043,085.87
		2.	Net profit attributable to non-controlling
			interests	-36,134,537.38	-22,816,029.89
6.	Other comprehensive income, net of tax			-53,899,251.86	-27,222,659.23
	Other	comprehensive income attributable to
	owners of the parent, net of tax			-53,895,260.68	-27,215,479.68
	(i)	Other comprehensive income that may not be
			reclassified to profit or loss
		1.	Changes arising from remeasurement
			under defined benefit plan
		2.	Other comprehensive income that may
			not be transferred to gain or loss
			under equity method
		3.	Change in fair value of investments in
			other equity instruments
		4.	Change in fair value of own credit risk
		5.	Others
	(ii)	Other comprehensive income that will be
			reclassified to profit or loss	-53,895,260.68	-27,215,479.68
		1.	Other comprehensive income that may
			be reclassified to profit or loss
			under equity method
		2.	Change in fair value of other debt
			investments
		3.	Amount included in other
			comprehensive income on
			reclassification of financial assets
		4.	Impairment allowance of other debt
			investments
		5.	Cash flow hedging reserve	2,693,355.32
		6.	Exchange difference on translation of
			foreign financial statements	-56,588,616.00	-27,215,479.68
		7.	Others
	Other	comprehensive income attributable to
	the	non-controlling interests, net of tax		-3,991.18	-7,179.55

Amount of the Amount of the Item current period previous period 7. Total comprehensive income 950,028,971.33 739,004,396.75 Total comprehensive income attributable to owners of the parent 986,167,499.89 761,827,606.19 Total comprehensive income attributable to the non-controlling interests -36,138,528.56 -22,823,209.44 8. Earnings per share: (i) Basic earnings per share 1.3131 0.9976 (ii) Diluted earnings per share 1.3104 0.9951 Person in charge of Legal representative: Chief Financial Officer: Accounting Department: LOU Boliang LI Shing Chung Gilbert LI Shing Chung Gilbert

3. Consolidated Statement of Cash Flows from the Beginning of the Year to the End of the Reporting Period

Unit: RMB

Item 1. Cash flows from operating activities: Cash received from sales of goods and rendering of services Net increase in customers deposits, due to banks and other financial institutions Net increase in placements from the Central Bank Net increase in placements from other financial institutions Cash received from premiums of original insurance contracts Net cash received from reinsurance business Net increase in deposit from policyholders and investment Cash received from interests, fees and commissions Net increase in placements from banks and other financial institutions Net increase in repurchase agreements Net cash received from securities trading brokerage Refunds of taxes and surcharges Other cash received relating to operating activities Sub-total of cash inflow from operating activities Cash paid for goods and services Net increase in loans and advances to customers Net increase in deposits with the Central Bank and other financial institutions Cash paid for compensation pay-outs of original insurance contracts Net increase in placements with banks and other financial institution Cash paid for interest, fees and commissions Cash paid for insurance dividends Cash paid to and on behalf of employees Cash paid for taxes and surcharges Other cash paid relating to operating activities Sub-total of cash outflow from operating activities Net cash flow from operating activities	Amount of the current period 5,410,437,911.75 206,726,404.39 70,201,767.29 5,687,366,083.43 1,195,602,709.33 2,189,642,114.14 182,306,092.47 704,039,573.30 4,271,590,489.24 1,415,775,594.19	Amount of the previous period 3,628,518,030.12 149,590,422.56 155,608,831.79 3,933,717,284.47 854,574,863.73 1,369,818,927.36 127,503,683.93 422,776,426.50 2,774,673,901.52 1,159,043,382.95

Item 2. Cash flow from investing activities: Cash received from disposal of investments Cash received from return on investments Net cash received from disposal of fixed assets, intangible assets and other long-term assets Net cash received from disposal of subsidiaries and other business entities Other cash received relating to investing activities Sub-total of cash inflows from investing activities Cash paid to acquire fixed assets, intangible assets and other long-term assets Cash paid to acquire investments Net increase in pledged loans Net cash paid to acquire subsidiaries and other business entities Other cash paid relating to investing activities Sub-total of cash outflows from investing activities Net cash flow from investing activities 3. Cash flow from financing activities: Cash received from capital contributions Including: Cash received from capital contributions by non-controlling shareholders of subsidiaries Cash received from borrowings Other cash received relating to financing activities Sub-total of cash inflows from financing activities Cash paid for repayments of borrowings Cash payment for distribution of dividends, profits or interest expenses Including: Dividends and profit paid by subsidiaries to non-controlling shareholders Other cash paid relating to financing activities Sub-total of cash outflow from financing activities Net cash flows from financing activities	Amount of the current period 3,090,929,847.28 61,602,961.84 1,441,158.84 3,153,973,967.96 1,548,135,347.27 4,933,742,547.94 1,022,609,528.71 1,072,500.00 7,505,559,923.92 -4,351,585,955.96 4,497,419,972.62 4,497,419,972.62 120,530,146.56 272,042,080.97 295,071,484.20 687,643,711.73 3,809,776,260.89	Amount of the previous period 678,062,900.00 12,527,187.47 3,125,872.28 693,715,959.75 806,971,253.28 2,626,187,390.51 50,849,649.93 21,760,550.90 3,505,768,844.62 -2,812,052,884.87 5,873,205.70 5,873,205.70 225,501,276.47 231,374,482.17 733,294,156.72 130,981,815.08 73,743,866.08 938,019,837.88 -706,645,355.71

Amount of the Amount of the current period previous period

Item

4. Effect of foreign exchange rate changes on cash and cash equivalents 5. Net increase in cash and cash equivalents Add: Period-beginning balance of cash and cash equivalents 6. Period-end balance of cash and cash equivalents	-17,019,209.79 856,946,689.33 2,353,933,839.46 3,210,880,528.79	-49,813,574.49
		-2,409,468,432.12 4,442,218,224.31
		2,032,749,792.19

(II) Description of Financial Statement Adjustment

1. Adjustment on items of the financial statements of the first year of adopting new leasing standards since 2021

□ Applicable √ N/A

2. Explanation of retrospective adjustment on comparative data of the first year of adopting new leasing standards since 2021

Applicable √ N/A

(III) Audit Report

Whether the Third Quarterly Report has been audited

□ Yes √ No

The Third Quarterly Report of the Company has not been audited.

(IV) Quarterly Condensed Consolidated Financial Statements Prepared in Accordance with IFRSs

1. Consolidated Statement of Profit or Loss[1]

For the nine months ended September 30, 2021

REVENUE
Cost of sales
Gross profit
Other income and gains
Other expenses
Selling and distribution expenses
Administrative expenses
Research and development costs
Impairment losses on financial and contract assets
Finance costs
Share of losses of associates
Profit before tax
Income tax expense
Profit for the period
Attributable to:
Owners of the parent
Non-controlling interests
EARNINGS PER SHARE ATTRIBUTABLE TO
ORDINARY EQUITY HOLDERS OF THE PARENT
Basic
For profit for the period
Diluted
For profit for the period

Nine months ended September 30,
2021
2020
RMB’000
RMB’000
5,301,533
3,585,968
(3,367,321)
(2,238,172)
1,934,212
1,347,796
214,433
205,639
(40,510)
(13,611)
(104,381)
(65,228)
(629,269)
(469,710)
(109,852)
(69,048)
(5,068)
(2,790)
(48,844)
(17,643)
(8,154)
(22,204)
1,202,567
893,201
(198,639)
(126,974)
1,003,928
766,227
1,040,063
789,043
(36,135)
(22,816)
1,003,928
766,227
RMB1.3131
RMB0.9976
RMB1.3104
RMB0.9951

1 Any discrepancies in data below between the total shown and the sum of the amounts listed are due to rounding.

2. Consolidated Statement of Financial Position[2]

September 30, 2021

NON-CURRENT ASSETS Property, plant and equipment Right-of-use assets Investment properties Goodwill Other intangible assets Investments in associates Equity investments at fair value through profit or loss Biological assets Deferred tax assets Other non-current assets Total non-current assets CURRENT ASSETS Inventories Contract costs Trade receivables Contract assets Biological assets Prepayments, other receivables and other assets Financial assets at fair value through profit or loss Derivative financial instruments Pledged deposits Cash and cash equivalents Total current assets CURRENT LIABILITIES Interest-bearing bank borrowings Trade payables Other payables and accruals Contract liabilities Lease liabilities Tax payable Total current liabilities NET CURRENT ASSETS TOTAL ASSETS LESS CURRENT LIABILITIES	September 30, 2021 RMB’000 5,062,216 656,066 – 1,813,810 180,578 375,738 282,254 39,136 15,557 455,790 8,881,145 175,849 189,005 1,162,676 187,237 202,696 785,623 1,632,060 29,893 23,130 4,266,742 8,654,911 425,838 283,662 999,412 662,178 88,737 92,065 2,551,892 6,103,019 14,984,164	December 31, 2020 RMB’000 3,841,445 567,630 43,889 1,166,172 189,976 280,474 121,230 – 8,436 149,162 6,368,414 128,757 152,860 1,076,614 133,764 – 196,020 825,312 84,698 7,263 2,935,090 5,540,378 386,146 191,497 819,313 473,289 83,925 27,620 1,981,790 3,558,588 9,927,002

NON-CURRENT LIABILITIES Interest-bearing bank borrowings Deferred tax liabilities Financial liabilities at fair value through profit or loss Deferred income Convertible bonds-debt component Convertible bonds-embedded derivative component Lease liabilities Total non-current liabilities NET ASSETS EQUITY Share capital Treasury shares Convertible bonds-equity component Reserves Equity attributable to owners of the parent Non-controlling interests Total equity	September 30, 2021 RMB’000 933,201 115,677 – 152,566 3,470,088 181,524 227,180 5,080,236 9,903,928 794,177 (145,241) 198,554 8,910,444 9,757,934 145,994 9,903,928	December 31, 2020 RMB’000 394,811 106,906 146,810 158,128 – – 186,608 993,263 8,933,739 794,387 (45,475) – 8,121,407 8,870,319 63,420 8,933,739

2 Any discrepancies in data below between the total shown and the sum of the amounts listed are due to rounding.

3. Non-IFRSs adjusted net profit for the period attributable to owners of the parent

To supplement the financial statements prepared by us, we use non-IFRSs adjusted net profit attributable to owners of the parent as an additional financial measure. We define non-IFRSs adjusted net profit attributable to owners of the parent as net profit before certain expenses/ (gains) as set out in the table below.

The Company believes that the consideration of the non-IFRSs adjusted net profit attributable to owners of the parent by eliminating the impact of certain incidental, non-cash or non-operating items is useful for better understanding and assessing underlying business performance and operating trends for the Company’s management, shareholders and potential investors.

The non-IFRSs adjusted net profit attributable to owners of the parent is not an alternative to (i) profit before tax or net profit (as determined in accordance with IFRSs) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to satisfy our cash needs, or (iii) any other measures of performance or liquidity. In addition, the presentation of the non-IFRSs adjusted net profit attributable to owners of the parent is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRSs. Shareholders and potential investors should not view the non-IFRSs adjusted net profit attributable to owners of the parent on a stand-alone basis or as a substitute for results under the IFRSs, or as being comparable to results reported or forecasted by other companies.

Profit attributable to owners of the parent
Add:
Share-based compensation expenses
Interest and issuance expense on convertible bonds
Losses on fair value change of convertible
bonds-embedded derivative component
Foreign exchange related (gains)/losses
Non-IFRS net profit attributable to owners of the parent
Add:
Realized and unrealized gains from equity investments
Non-IFRS adjusted net profit attributable to owners
of the parent

Nine months ended September 30,
2021
2020
RMB’000
RMB’000
1,040,063
789,043
39,382
43,906
33,126
–
27,111
–
(18,768)
11,377
1,120,914
844,326
(73,033)
(82,757)
1,047,881
761,569

AI assistant

Pharmaron Beijing Co., Ltd Interim / Quarterly Report 2021

50881_rns_2021-10-27_6b8d9fd5-2793-4be4-9576-324ba3b4962a.pdf